Zymeworks Strategy and Business Model

Executive Overview

Zymeworks is a biotechnology company focused on engineered antibody therapeutics, with a particular emphasis on oncology. Founded in 2003 and headquartered in Vancouver, British Columbia, the company built its identity around proprietary platforms for bispecific and multispecific antibodies, Fc engineering, and newer antibody-drug conjugate design. Strategically, Zymeworks sits between a platform company and a product company: it uses its technology both to create wholly owned pipeline assets and to strike licensing or collaboration deals with larger pharmaceutical companies that can fund development and commercialization at scale.

Its best-known asset is zanidatamab, a HER2-targeted bispecific antibody that has been partnered for major territories, while Zymeworks continues to advance earlier-stage internal programs in antibody-drug conjugates and related biologics. That structure is important for understanding the company’s economics. Zymeworks has historically depended more on collaboration revenue, milestones, and future royalty potential than on broad self-commercialized product sales. Operationally, it combines internal discovery, translational science, and portfolio management with outsourced manufacturing and clinical execution. For FY2024, reported revenue was #N/A, reflecting the partnership-heavy nature of the model.

Zymeworks at a Glance

Logo
Common name	Zymeworks
Full legal name	Zymeworks Inc.
Headquarters	Vancouver, British Columbia, Canada
Ownership	Publicly traded; no controlling shareholder disclosed in the company’s public filings as of 2024
Ticker	ZYME
Exchange	NASDAQ
Market Cap	$1.74B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2003; built antibody-engineering platforms; went public in 2017; later partnered zanidatamab and redomiciled to Delaware in 2022
Industry or industries	Biotechnology; oncology therapeutics; biologics discovery and development
Key products or services	Engineered antibody therapeutics, including bispecific antibodies and antibody-drug conjugates; platform licensing and collaboration
Geographic footprint	Operational footprint centered in Canada and the United States, with clinical and commercial reach extended through global trial networks and regional partners
Business segments as officially reported	One operating and reportable segment
Company website	https://www.zymeworks.com/

1. What Is the Strategy of Zymeworks?

Zymeworks’ public materials describe a strategy built around differentiated biologics, disciplined portfolio focus, and selective partnering. Using the Playing to Win framework, the company’s strategy can be understood as follows.

1a. What is the winning aspiration of Zymeworks?

Zymeworks’ winning aspiration is to create clinically meaningful biologic therapies for patients with hard-to-treat cancers while capturing value from its antibody-engineering platforms. In practical terms, “winning” for Zymeworks does not look like broad primary-care scale or a sprawling commercial footprint. It looks like producing molecules that are differentiated enough to achieve regulatory success, attract strong partners, and generate milestones and royalties that can fund the next wave of innovation.

Unlike large pharmaceutical companies, Zymeworks has not centered its public messaging on long-range revenue or margin targets. Its more concrete value markers have been clinical data, regulatory progress, partnership economics, and preservation of cash runway.
1b. Where does Zymeworks play?

Zymeworks plays primarily in oncology, especially settings where antibody engineering may improve target binding, overcome resistance, or enable more selective payload delivery. Its best-known work has centered on HER2, but its platform and pipeline strategy extends to other validated oncology targets suitable for bispecific antibodies or antibody-drug conjugates.

Geographically, Zymeworks plays globally through partners rather than by building a full global commercial infrastructure on its own. Customer-wise, its immediate paying counterparties are often larger biopharmaceutical companies that license programs or territories, while the eventual end users are oncologists, infusion centers, hospitals, and patients.
1c. How does Zymeworks plan to win?

Zymeworks plans to win by combining molecule differentiation with capital efficiency. The differentiation comes from proprietary antibody-engineering technologies such as Azymetric and EFECT, plus newer antibody-drug conjugate capabilities. The capital efficiency comes from partnering later-stage or geographically broad commercial opportunities with larger companies that can absorb launch costs and regulatory complexity.

That is an important point. Zymeworks is not trying to outspend large oncology companies in commercialization. It is trying to out-design molecules, prove value clinically, and then capture a meaningful share of the economics through licensing structures and retained pipeline ownership.
1d. What capabilities must Zymeworks have in place?

To execute this strategy, Zymeworks needs strong capabilities in protein engineering, translational biology, biomarker-informed drug development, clinical strategy, regulatory execution, and alliance management. It also needs the ability to manage Chemistry, Manufacturing, and Controls (CMC) activities through external partners, since clinical-stage biotechs commonly outsource large portions of manufacturing and trial execution.

Equally important are intellectual-property management and disciplined portfolio selection. In a company of Zymeworks’ scale, the ability to stop, pause, or partner programs at the right moment is as strategic as scientific innovation itself.
1e. What management systems does Zymeworks require?

Zymeworks requires management systems that support milestone-driven portfolio decisions. That includes stage-gate R&D governance, formal alliance-management processes with partners, rigorous quality and compliance systems for outsourced development and manufacturing, and cash-planning processes tied to expected clinical and regulatory milestones.

For a biotech with a mix of partnered and wholly owned programs, management systems also need to balance two time horizons: near-term value inflection from partnered late-stage assets and longer-term value creation from the earlier internal pipeline.

2. What Are the Current Strategic Initiatives of Zymeworks?

Based on the company’s public materials through 2024, Zymeworks’ strategic initiatives appear concentrated in a small number of high-value priorities rather than in broad diversification.

Support the regulatory and commercial path for zanidatamab. Zymeworks’ lead partnered asset has been zanidatamab, a HER2-targeted bispecific antibody. A major near-term initiative has been supporting partner-led development, regulatory filing work, and commercialization preparation in target indications such as biliary tract cancer and other HER2-expressing tumors.
Broaden the clinical evidence base for HER2-directed programs. Beyond a single indication, the strategic logic is to expand the addressable opportunity for zanidatamab through additional tumor settings, combinations, and treatment lines where HER2 biology is relevant.
Build the next wave of wholly owned pipeline assets. Zymeworks has emphasized advancing new antibody-drug conjugate and multispecific candidates from its internal platforms. In 2024 company materials, it highlighted newer preclinical oncology candidates aimed at targets such as folate receptor alpha, Nectin-4, and glypican-3, signaling a deliberate effort to create a second engine of value beyond zanidatamab.
Use platform technologies as both a discovery engine and a partnering asset. The company’s platforms are not just internal tools. They also support licensing and collaboration discussions with larger drugmakers that may want access to differentiated biologics or territory rights.
Maintain capital discipline. Zymeworks has publicly emphasized prioritization and financial focus. For a clinical-stage biotech, that means concentrating resources on the programs with the clearest probability-adjusted value creation and avoiding the cost structure of a fully built commercial oncology company before it is justified.

3. What Is the Business Model of Zymeworks?

What customers actually buy

Today, the clearest thing customers buy from Zymeworks is access to drug candidates and platform-derived intellectual property. In other words, the company’s present-day customers are often pharmaceutical partners rather than end-market healthcare providers. A partner may buy territorial rights to a program, global development rights, or access to platform-enabled discovery capabilities. Over time, if therapies are approved and commercialized, the end market becomes oncologists, hospitals, infusion centers, and payers, but in several important territories Zymeworks has chosen to reach those customers through partners.

Recurring versus one-time economics

Zymeworks’ economics are only partly recurring. Upfront payments and development milestones are typically one-time or event-driven. Royalties, if achieved, are more recurring, but they depend on regulatory success and sustained commercialization by partners. That makes the revenue model structurally different from a subscription business or from a mature pharmaceutical company with a broad marketed portfolio.

How pricing power works

At the corporate level, Zymeworks’ current pricing power is limited because much of the near-term economic value comes from deal terms, milestone structures, and royalty rates rather than from directly setting product prices. At the product level, future pricing power depends on whether its therapies show clinically meaningful differentiation in efficacy, safety, convenience, or resistance management compared with other HER2-targeted therapies and oncology biologics.

Why the business mix matters

The mix between partnered late-stage assets and wholly owned early-stage assets is central to the model. A partnered program can reduce capital needs and regulatory burden while still generating economic upside. The wholly owned pipeline preserves strategic optionality and can create future partnering leverage. If Zymeworks were only a royalty vehicle, it would look very different. If it were only an early research platform company, it would also look different. Its model sits in between.

What drives margins and cash generation

For Zymeworks, gross margin is less informative than it would be for a manufacturer or mature pharma company, because revenue is weighted toward licensing and collaboration accounting. Operating margin is usually dominated by research and development expense, clinical spending, technical operations, and general corporate costs. Cash generation depends heavily on milestone timing, partner reimbursements, capital raises, and expense discipline. In short, this is a value-inflection business, not a steady high-volume sales business.

4. What Products and/or Services Does Zymeworks Sell?

Zymeworks’ offerings are best understood in four categories.

Zanidatamab and related economics. The company’s most important asset has been zanidatamab, a HER2-targeted bispecific antibody discovered using Zymeworks technology. Strategically, this is the program with the clearest near-term value potential because it sits closest to commercialization and can generate milestones and royalties through partners.
Wholly owned pipeline candidates. Zymeworks has been building a next generation of antibody-drug conjugate and multispecific programs. These earlier-stage assets are not yet broad commercial products, but they are strategically important because they can become future pipeline anchors or partnering assets.
Platform technologies. Zymeworks’ proprietary platforms, especially Azymetric and EFECT, are part of what it effectively “sells” to the market. Sometimes that value is embedded inside internally developed drug candidates. In other cases, it can support external collaborations and licensing.
Drug-development know-how and partnership value. For a company like Zymeworks, the service-like offering is not contract research in the traditional sense. It is the ability to originate differentiated biologics, generate data, manage development, and structure transactions with larger pharmaceutical companies.

There is no real legacy-versus-newer-products split in the way one would see at an established pharmaceutical company. Instead, the more relevant distinction is between later-stage partnered assets and earlier-stage wholly owned pipeline programs.

5. What Are the Key Competitors or Peers of Zymeworks?

Zymeworks’ competitive set is mixed. It competes partly against companies developing HER2-directed oncology therapies and partly against platform-biotech peers building bispecific antibodies or antibody-drug conjugates.

AstraZeneca / Daiichi Sankyo — A major therapeutic competitor because Enhertu is a leading HER2-directed antibody-drug conjugate across multiple solid-tumor settings.
Roche / Genentech — An established HER2 franchise leader through therapies such as Herceptin, Perjeta, Kadcyla, and related combinations. Roche is especially relevant as a benchmark for clinical standards in HER2-positive disease.
MacroGenics — A closer biotech peer in antibody therapeutics, with HER2 relevance through margetuximab and broader experience in Fc engineering and oncology biologics.
Merus — A close platform peer focused on multispecific antibodies in oncology. Merus is not a mirror image of Zymeworks, but the two are often compared as engineered-antibody companies trying to create differentiated biologics through format innovation.
Genmab — A strong antibody-innovation peer with deep partnering experience, bispecific capabilities, and a track record of turning platform science into high-value products and alliances.
Regeneron — A larger and more diversified antibody competitor whose platform breadth, biologics capabilities, and oncology pipeline make it a relevant comparator, especially on scientific execution.
Pfizer / Seagen — Particularly relevant on antibody-drug conjugates and oncology commercialization, even if not always a direct program-by-program rival.
Amgen — More of a modality and business-model comparable than a direct HER2 competitor, but important as a large oncology-biologics company with deep experience in engineered multispecific formats.

The key analytical point is that Zymeworks is not competing only against other small biotechs. Once a program reaches late-stage oncology development, it competes for physician attention, trial enrollment, partner interest, and payer relevance against much larger companies with established cancer franchises.

6. What Is the Marketing Strategy of Zymeworks?

Zymeworks’ marketing strategy is closer to scientific and business-development marketing than to consumer or mass-market pharmaceutical promotion. Because the company has historically operated as a development-stage biotech with partnered commercialization in key territories, the most important “marketing” tools are clinical data, publications, conference presentations, key opinion leader relationships, and partner credibility.

In practice, that means medical congresses, peer-reviewed publications, investigator engagement, and clear communication of differentiated biology matter more than broad advertising. For the company’s platform and partnering activities, business development also functions as a form of account-based marketing: the audience is not the general public but a relatively small set of pharmaceutical decision-makers who evaluate strategic fit, scientific novelty, and deal economics.

Marketing is therefore a supporting capability rather than the core source of advantage. The core differentiator is the underlying science and the clinical evidence generated from that science.

7. What Are the Key Customer Segments of Zymeworks?

Zymeworks’ customer base looks different from that of a mature biopharma company because its current economic counterparties are narrower and more specialized.

Pharmaceutical and biotechnology partners. These are the most important current paying customers in a business-model sense. They may license territory rights, collaborate on development, or evaluate the company’s platform-enabled assets.
Oncology prescribers and cancer centers. These are the eventual clinical customers for approved therapies, although in many important markets the interface is likely to be led by partners rather than Zymeworks directly.
Payers and health systems. These matter indirectly because reimbursement and formulary acceptance influence the commercial value of oncology therapies even when Zymeworks is not the direct seller.
Clinical investigators and trial networks. They are not customers in an accounting sense, but they are strategically critical stakeholders because they shape development speed, data quality, and clinical adoption pathways.

Overall, Zymeworks is more concentrated than a diversified commercial pharma company. A small number of high-value partners and a small number of strategically important oncology programs matter disproportionately.

8. What Is the Sales Model of Zymeworks?

Zymeworks’ present-day sales model is primarily partnering-led, not field-force-led. The company’s most consequential “sales” activity is business development: negotiating licenses, collaborations, and territory arrangements around its pipeline assets and technology. That is very different from selling a mature drug portfolio through a large specialty-sales organization.

For end-market commercialization, the model is partner-enabled in major territories. That lowers fixed costs and reduces the need to build a full global oncology sales and market-access infrastructure internally. The trade-off is that Zymeworks gives up some direct customer intimacy and some share of downstream economics in exchange for speed, scale, and lower operating risk.

This channel structure affects growth in a few important ways. It can accelerate market entry where a larger partner already has oncology relationships and reimbursement capabilities. It can also reduce pricing control and direct commercial learning for Zymeworks itself. From a consulting perspective, this structure often creates demand for alliance management, launch governance, indication prioritization, and partner-performance tracking rather than for pure sales-force expansion work.

9. In What Geographies Does Zymeworks Operate?

Zymeworks is headquartered in Vancouver, Canada, and has operated with a North America-centered internal footprint. Its operational base is much smaller than its effective market reach because the company uses external partners, contract organizations, and global clinical-trial networks.

Commercially and clinically, its reach is international. Zanidatamab rights have been divided among regional partners, allowing the program to extend into major Western markets and selected Asian territories without Zymeworks having to build all of that infrastructure itself. Clinical development in oncology also tends to be multinational, so even when internal headcount is concentrated in Canada and the United States, the trial footprint can span North America, Europe, and Asia.

Zymeworks is therefore geographically concentrated in terms of owned infrastructure but geographically broad in terms of where its science, clinical programs, and partnered commercial opportunities can reach.

10. Who Are the Owners of Zymeworks?

Zymeworks is a publicly traded company listed under the ticker ZYME. As of the company’s 2024 public filings, it did not disclose a controlling shareholder. Its ownership structure appears typical of a small-cap biotechnology company: institutional investors, specialist healthcare funds, and other public-market investors hold the shares, with positions capable of changing materially over time.

11. How Is Zymeworks Organized?

Officially, Zymeworks reports one operating and reportable segment. Practically, though, the company can be understood as being organized around several core activities.

Discovery and platform research — antibody engineering, target selection, and early molecule design.
Preclinical and translational development — biologic characterization, biomarker work, toxicology planning, and candidate selection.
Clinical development and regulatory affairs — study design, clinical oversight, safety, data analysis, and agency interactions.
Technical operations / CMC — process development, manufacturing oversight, analytical methods, and supply management through external partners.
Business development and alliance management — structuring partnerships and coordinating with licensees such as commercialization partners.
Corporate functions — finance, legal, intellectual property, investor relations, and public-company infrastructure.

A useful way to think about the company is that it has one legal and reporting segment, but two strategic portfolios: partnered late-stage assets and wholly owned earlier-stage assets.

12. How Does Zymeworks Operate?

On a day-to-day basis, Zymeworks operates like a platform-enabled clinical-stage biotech. It starts with target and modality selection, engineers antibodies or antibody-drug conjugates using its proprietary technologies, and then moves candidates through preclinical characterization toward human studies or licensing transactions.

Much of the operating complexity comes from coordination rather than from owned industrial scale. Zymeworks relies on third parties for many laboratory, clinical, and manufacturing activities, so execution depends on vendor management, data integration, quality oversight, and regulatory discipline. For partnered programs, operations also include governance with external companies that may control certain development or commercial decisions in licensed territories.

The biggest operational performance drivers are typically candidate quality, clinical execution speed, manufacturing readiness, and disciplined capital allocation. The main bottlenecks are familiar to biotech investors and operators: trial enrollment, Chemistry, Manufacturing, and Controls readiness, analytical comparability, regulatory timing, and the risk that one delayed milestone can affect both cash planning and portfolio sequencing.

13. What Are the Growth Opportunities for Zymeworks?

Zymeworks’ most plausible growth opportunities fall into a few clear buckets.

Zanidatamab commercialization and royalties. The most immediate value opportunity is successful registration and uptake of zanidatamab in target oncology indications, which can translate into milestones and royalty streams.
Label expansion across HER2-driven tumors. If clinical data support use in additional tumor types, earlier lines of therapy, or rational combinations, the economic value of the program can widen materially.
Advancement of wholly owned next-generation programs. New antibody-drug conjugate and multispecific assets can create future partnering leverage or internal pipeline value beyond the company’s current lead asset.
Platform-enabled partnerships. Zymeworks can grow through additional licensing or collaboration transactions that monetize its engineering capabilities without requiring full self-commercialization.
Strategic portfolio reshaping. As with many biotechs, growth may come not only from advancing assets but from deciding which assets to retain, which to partner, and where to concentrate internal capital.

The main constraints are also clear: clinical and regulatory risk, manufacturing complexity, dependence on partner execution in licensed territories, competitive pressure from larger oncology companies, and the need to preserve enough capital to reach meaningful value-inflection points.

14. What Is the History of Zymeworks?

Zymeworks was founded in 2003 in Vancouver, British Columbia, and built its early identity around computational and experimental antibody engineering. Over time, it developed proprietary platforms such as Azymetric and EFECT and used them both for internal pipeline creation and for collaborations with larger pharmaceutical companies.

A major corporate milestone came with its 2017 public listing, which gave it wider access to capital markets. In the following years, zanidatamab emerged as the company’s lead asset and the clearest demonstration of its platform capabilities. Zymeworks also entered strategic regional licensing arrangements around zanidatamab, including a major partnership with Jazz Pharmaceuticals and an earlier regional deal in Asia.

In 2022, the company underwent a significant strategic reset that included sharper portfolio prioritization and a redomicile from British Columbia to Delaware. By 2023 and 2024, the company’s profile had evolved into a more focused model: support the partnered lead asset, preserve financial flexibility, and rebuild a next generation of wholly owned oncology programs from its technology base.

15. What Are the Key Suppliers to Zymeworks?

Suppliers matter a great deal to Zymeworks because it operates with a relatively asset-light physical footprint and relies heavily on external specialist organizations. The most important supplier categories are:

Contract research organizations (CROs) for clinical trial management, site monitoring, data management, and statistical support.
Contract development and manufacturing organizations (CDMOs) for biologic drug substance production, fill-finish, process development, and analytical testing.
Specialized laboratory providers for bioanalytical assays, biomarker work, toxicology, and other preclinical services.
Suppliers of biologics raw materials such as cell-culture media, resins, reagents, and consumables that can become single-source constraints.
Cold-chain and clinical logistics providers that move investigational product to trial sites and, eventually, commercial channels managed by partners.

Zymeworks has publicly disclosed the general importance of third-party suppliers and manufacturers, even if it does not always name them. Supplier structure matters strategically because a quality issue, capacity shortage, or tech-transfer delay at a third party can push back clinical timelines and regulatory milestones.

16. How Does the Supply Chain of Zymeworks Function?

Zymeworks’ supply chain is typical of a clinical-stage biologics company: scientifically complex, heavily outsourced, and highly sensitive to regulatory quality. Rather than running a large owned manufacturing network, the company coordinates a chain that usually includes cell-line development, upstream and downstream biologics manufacturing, formulation, fill-finish, release testing, packaging, and cold-chain distribution.

For clinical programs, the supply chain must support relatively small but highly controlled batch sizes, trial-specific labeling, and international shipment to investigative sites. As assets move closer to registration, the requirements tighten around validation, comparability, process robustness, and inspection readiness.

This means Zymeworks’ real supply-chain challenge is orchestration: selecting the right CDMOs, building enough redundancy where possible, maintaining documentation quality, and ensuring that development, regulatory, and manufacturing timelines stay aligned.

17. What Are the Key Assets of Zymeworks?

Zymeworks is not asset-heavy in the factory or infrastructure sense. Its most important assets are scientific, intellectual, and financial.

Proprietary antibody-engineering platforms such as Azymetric and EFECT, plus related know-how in multispecific and conjugated biologics.
Clinical and regulatory data packages associated with lead programs, especially zanidatamab.
Economic rights under partnerships including milestones, royalties, and other contractual value tied to partnered assets.
Wholly owned pipeline candidates that can become future development or partnering assets.
Cash and marketable securities, which are strategic assets in biotech because they buy time to reach clinical inflection points without forced financing.
Human capital and intellectual property in protein engineering, translational oncology, and alliance management.

In biotech, these assets often matter more than physical plant because they determine optionality, bargaining power, and the ability to create differentiated molecules.

18. What Is the Technology Strategy of Zymeworks?

Zymeworks’ technology strategy is central to its identity. The company has aimed to build reusable platforms that improve how antibodies are designed, combined, and optimized rather than relying on single-asset trial-and-error. Its best-known technologies include Azymetric for bispecific and multispecific antibodies and EFECT for Fc optimization, supplemented by newer antibody-drug conjugate capabilities.

That strategy serves two purposes. First, technology acts as an internal enabler, allowing Zymeworks to generate wholly owned product candidates with differentiated design features. Second, technology acts as an external value proposition, since platform credibility supports licensing discussions and partnership economics.

Where technology appears most central to competitiveness is in the company’s attempt to create molecules that are not just incrementally different, but structurally better suited for difficult oncology targets. For Zymeworks, technology is not a back-office function. It is the core of how the company chooses where to play and how to win.

19. What Is the R&D Strategy of Zymeworks?

R&D is the center of gravity for Zymeworks. The company’s research strategy has been to focus on oncology targets where antibody engineering can produce a clinically meaningful edge, whether through dual-target or dual-epitope engagement, altered effector function, or targeted payload delivery.

Its development strategy appears to balance three goals:

Advance high-value lead assets far enough to prove differentiation.
Create a replenishing pipeline from proprietary platforms.
Use partnerships where they improve risk-sharing and commercialization reach.

An important aspect of the strategy is prioritization. Zymeworks has signaled a willingness to focus resources on fewer programs with clearer strategic logic rather than trying to support too many clinical and preclinical assets at once. For a company of its size, that is as much an R&D strategy as a finance strategy.

20. What Is the Finance Strategy of Zymeworks?

Zymeworks’ finance strategy is built around preserving runway, funding value-creating R&D, and using partnerships to avoid the fixed-cost burden of self-commercializing globally before the portfolio can support it. For a company at this stage, liquidity is strategic. The company’s bargaining power in licensing discussions and its ability to withstand clinical delays both depend heavily on cash position and burn control.

Publicly, the company has emphasized disciplined capital allocation. That generally means prioritizing the most promising programs, relying on milestone-bearing partnerships where appropriate, and avoiding unnecessary commercial overhead. Zymeworks is not a dividend or buyback story; capital is primarily reinvested in discovery, development, CMC readiness, and corporate flexibility.

The underlying finance logic is straightforward: reach the next important data or regulatory milestone with enough balance-sheet strength to preserve options, rather than forcing strategic decisions because of short-term liquidity pressure.

21. How Companies Like Zymeworks Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. Companies like Zymeworks use Umbrex when they need highly experienced problem-solvers in strategy, operations, organization, finance, marketing, sales, technology, ERP, or AI, but do not need a full traditional consulting team with the associated overhead. For a biotechnology company balancing partnered assets, internal pipeline development, outsourced operations, and cash discipline, that model can be especially useful.

Representative projects for a company like Zymeworks include:

Portfolio prioritization: evaluate which pipeline programs should be funded internally, partnered, paused, or stopped based on probability-adjusted value and strategic fit.
Indication expansion strategy: assess the best tumor types, lines of therapy, and combination pathways for HER2-directed assets and next-generation biologics.
Alliance-management support: design governance dashboards and milestone-tracking processes for partnered programs with regional or global licensees.
Commercial opportunity assessment: size market potential, treatment flows, pricing analogs, and market-access hurdles for oncology assets that may be commercialized through partners.
Business development target screening: identify potential licensing partners, co-development structures, or in-licensing opportunities that fit Zymeworks’ technology and capital strategy.
R&D operating model redesign: improve decision rights, stage-gate governance, and resource allocation across discovery, translational, and clinical teams.
CMC and external-network strategy: assess CDMO footprint, tech-transfer risk, dual-sourcing options, and readiness for later-stage manufacturing requirements.
Clinical operations improvement: streamline trial startup, site prioritization, vendor governance, and milestone reporting for complex oncology studies.
Finance and runway planning: build scenario models linking trial timing, partnership milestones, burn rate, and capital-allocation choices.
AI-enabled competitive intelligence and evidence synthesis: create workflows for literature surveillance, congress monitoring, and structured insight generation across HER2, bispecific, and antibody-drug conjugate markets.